AR044380A1 - Forma de dosificacion farmaceutica que comprende una solucion solida - Google Patents

Forma de dosificacion farmaceutica que comprende una solucion solida

Info

Publication number
AR044380A1
AR044380A1 ARP040101711A ARP040101711A AR044380A1 AR 044380 A1 AR044380 A1 AR 044380A1 AR P040101711 A ARP040101711 A AR P040101711A AR P040101711 A ARP040101711 A AR P040101711A AR 044380 A1 AR044380 A1 AR 044380A1
Authority
AR
Argentina
Prior art keywords
dosage form
solid solution
pharmaceutical dosage
pharmaceutical
naloxone
Prior art date
Application number
ARP040101711A
Other languages
English (en)
Inventor
Hubert Rein
Klaus-Juergen Steffens
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR044380A1 publication Critical patent/AR044380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para producir una forma de dosificación farmacéuticamente que es una solución sólida donde dicha forma de dosificación se produce extruyendo una mezcla humedecida en exceso de por lo menos un compuesto con actividad farmacéutica, como por ejemplo oxicodona y naloxona, entre otros, y por lo menos un polisacárido, como por ejemplo: almidón de maíz, de papa o de tapioca.
ARP040101711A 2003-05-19 2004-05-18 Forma de dosificacion farmaceutica que comprende una solucion solida AR044380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011029A EP1479381A1 (en) 2003-05-19 2003-05-19 Pharmaceutical dosage form comprising a solid solution

Publications (1)

Publication Number Publication Date
AR044380A1 true AR044380A1 (es) 2005-09-07

Family

ID=33040941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101711A AR044380A1 (es) 2003-05-19 2004-05-18 Forma de dosificacion farmaceutica que comprende una solucion solida

Country Status (3)

Country Link
EP (1) EP1479381A1 (es)
AR (1) AR044380A1 (es)
WO (1) WO2004100930A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP2214672B1 (en) 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
DE102011015370A1 (de) * 2011-03-29 2012-10-04 Emodys Gmbh Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
KR20200072445A (ko) * 2017-03-28 2020-06-22 엘디엔 파마 리미티드 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture

Also Published As

Publication number Publication date
EP1479381A1 (en) 2004-11-24
WO2004100930A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
BRPI0514474A (pt) multiparticulados
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
ME01324B (me) Derivati 1-tio-d-glucitola
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
AR049839A1 (es) Procedimiento para la produccion deuna forma farmaceutica solida, protegida frente al abuso
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
ATE489365T1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
CR8593A (es) Procesos para preparar clorhidrato de oxicodona teniendo menos de 25 ppm 14-hidroxicodeinona
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
CY1106478T1 (el) Μεθοδος για την παραγωγη αμορφης επιβραδυντικης μητρας μη διαλυτης στο υδωρ
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
AR044380A1 (es) Forma de dosificacion farmaceutica que comprende una solucion solida
DE602006011139D1 (de) Herstellungsverfahren für silylisocyanurat
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
EP2543681A4 (en) METHOD FOR THE PRODUCTION OF CATIONULATED CELLULOSE AND METHOD FOR THE PRODUCTION OF CATIONIZED HYDROXYALKYL CELLULOSE
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
ATE432710T1 (de) Pharmazeutische zusammensetzungen, die diaminooxidase enthalten

Legal Events

Date Code Title Description
FB Suspension of granting procedure